Intravenous thrombolysis in stroke patients taking novel oral anticoagulants: experience with the low-dose 0.6 mg/kg of recombinant tissue-type plasminogen activator. Case reports

•The novel oral anticoagulant (NOACs) have been approved for stroke prevention in patients with atrial fibrillation.•Routine administration of IV rt-PA in patients taking NOACs is not recommended and caution should be applied when considering thrombolysis.•Treatment with low-dose 0.6 mg/kg alteplase could be a valid option in patients with ischemic stroke receiving NOACs.